StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research report released on Saturday morning. The firm issued a sell rating on the medical research company’s stock.
Organovo Stock Down 7.8 %
Shares of NASDAQ ONVO opened at $0.95 on Friday. The company has a market cap of $9.54 million, a price-to-earnings ratio of -0.44 and a beta of 0.87. The firm’s fifty day moving average is $1.04 and its 200 day moving average is $1.11. Organovo has a 52 week low of $0.89 and a 52 week high of $2.05.
Organovo (NASDAQ:ONVO – Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The medical research company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.08 million. Equities research analysts anticipate that Organovo will post -1.74 earnings per share for the current year.
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Five stocks we like better than Organovo
- How Can Investors Benefit From After-Hours Trading
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Market Cap Calculator: How to Calculate Market Cap
- 3 Value Stocks You Can Buy Before They Become Big
- The 3 Best Fintech Stocks to Buy Now
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
